Daunorubicin

About

Therapy type: Chemotherapy

Therapy strategy: DNA Polymerase inhibition

Mappings

NCI Thesaurus: Daunorubicin (ncit:C62091)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835Y Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835A Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835E Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835H Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835N Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835S Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.D835V Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3 p.I836del Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) CDK12 oncogenic variants Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) CD33 + Acute Myeloid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
Sensitivity (+) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
Sensitivity (+) CD33 + Acute Lymphoid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin